Cogent Biosciences reports FY2022 net loss $140.2M, cash $259.3M; outlines bezuclastinib milestones for 2023

Cogent Biosciences, Inc.

Net loss $39.6M Q4, $140.2M FY2022 vs $72.3M FY2021; R&D expenses $121.6M FY2022.
Cash, equivalents and marketable securities $259.3M as of Dec 31, 2022; runway into 2025.
APEX Part 2 initiation planned mid-2023; updated Phase 3 PEAK lead-in data expected 1H23.
Initial SUMMIT Phase 2 data in nonadvanced systemic mastocytosis expected 2H23.
Appointed Rachael Easton, M.D., Ph.D., VP Head of Clinical Development; Sylvia Adams to SAB.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Cogent Biosciences, Inc. reported financial results for the fourth quarter and full year of 2022.

Period: the fourth quarter and full year of 2022
Result: reported results

Exact text from the filing

On March 14, 2023, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Cogent Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-007717

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.